Effect of subconjunctival bevacizumab on primary pterygium

Cornea

Volumn 28, Issue 4, 2009, Pages 468-470

  Teng, Christopher C ^a,b   Patel, Nandesh N ^a,b   Jacobson, Lawrence ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

Author keywords

Bevacizumab; Pterygium

Indexed keywords

BEVACIZUMAB; MOXIFLOXACIN; PROXYMETACAINE;

ADULT; ARTICLE; CASE REPORT; CORNEA VASCULARIZATION; EYE COLOR; EYE IRRITATION; HUMAN; MALE; PRIORITY JOURNAL; PTERYGIUM; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; HUMANS; MALE; MIDDLE AGED; PTERYGIUM; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67650630978     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31818d382d     Document Type: Article

References (19)

1. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10:282-288.
2. Cameron ME. Histology of pterygium: an electron microscopic study. Br J Ophthalmol. 1983;67:604-608.
3. Hill JC, Maske R. Pathogenesis of pterygium. Eye. 1989;3:218-226.
4. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium - derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473-477.
5. Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001;20: 738-742.
6. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69: 925-927.
7. Kuo CH, Miyazaki D, Nawata N, et al. Prognosis-determinant candidate genes identified by whole genome scanning in eyes with pterygia. Invest Ophthalmol Vis Sci. 2007;48:3566-3575.
8. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor, and tumor necrosis factor a in primary pterygium. Acta Histochem. 1996;98:195-201.
9. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol. 1998;236:702-708.
10. Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology. 2005;112:1023-1030.
11. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombo-spondin-1. Eye. 2007;21:1095-1101.
12. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660-668.
13. Raiskup F, Solomon A, Landau D, et al. Mitomycin C for pterygium: long term evaluation. Br J Ophthalmol. 2004;88:1425-1428.
14. Riedel F, Götte K, Bergler W, et al. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck. 2000;22:183-189.
15. Esquenazi S. Treatment of early pterygium recurrence with topical administration of interferon alpha-2b. Can J Ophthalmol. 2005;40: 185-187.
16. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28.
17. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
18. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
19. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.